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Complement Factor H: A Biomarker for Progression of
Cutaneous Squamous Cell Carcinoma
Pilvi M. Riihila¨1,2, Liisa M. Nissinen1,2, Risto Ala-aho1,2, Markku Kallajoki3, Reidar Gre´nman4, Seppo Meri5,
Sirkku Peltonen1, Juha Peltonen6 and Veli-Matti Ka¨ha¨ri1,2
The incidence of cutaneous squamous cell carcinoma (cSCC) is increasing globally. We have studied the
expression of complement system components in cSCC. Expression profiling of cSCC cell lines (n¼ 8) and
normal human epidermal keratinocytes (n¼ 5) with Affymetrix and quantitative real-time PCR (qPCR) revealed
upregulation of complement factor H (CFH) and factor H-like protein-1 (FHL-1) in cSCC cell lines. The expression
of CFH and FHL-1 mRNAs was also significantly higher in cSCC tumors (n¼ 6) than in normal skin (n¼ 11).
Analysis of CFH and FHL-1 expression in vivo in invasive cSCCs (n¼ 65), in situ cSCCs (n¼ 38), and premalignant
lesions (actinic keratoses, n¼ 37) by immunohistochemistry showed that they were specifically expressed by
tumor cells in cSCCs and the staining intensity was stronger in cSCCs than in in situ cSCCs and actinic keratoses.
The expression of CFH by cSCC cells was upregulated by IFN-g and the basal CFH and FHL-1 expression was
dependent on extracellular signal–regulated kinase (ERK)1/2 and p38 signaling. Knockdown of CFH and FHL-1
expression inhibited proliferation and migration of cSCC cells and inhibited basal ERK1/2 activation. These results
provide evidence for a role of CFH and FHL-1 in cSCC progression and identify them as progression markers and
potential therapeutic targets in SCCs of skin.
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INTRODUCTION
The incidence of nonmelanoma skin cancer is increasing
globally and cutaneous squamous cell carcinoma (cSCC),
which constitutes approximately 20% of nonmelanoma skin
cancer cases, is the second most common cutaneous malig-
nancy in white population worldwide (Rogers et al., 2010).
Solar UV radiation is the major risk factor for cSCC and other
important risk factors include chronic ulceration of skin and
immunosuppression (Madan et al., 2010). Inflammation is
detected in a subset of cSCC and its precursors, actinic
keratosis (AK) and cSCC in situ (cSCCIS, Bowen’s disease),
as in many other types of cancer (Coussens and Werb, 2002;
Ratushny et al., 2012).
Complement system is an important part of host defense
in the innate immune system and its function is to destroy
microbes and apoptotic cells, and initiate the inflammatory
response (Ricklin et al., 2010, Rutkowski et al., 2010).
Complement system consists of three distinct pathways, i.e.,
classical, alternative, and lectin pathway, that converge and
activate complement C3 resulting in the formation of
membrane attack complex (MAC) and lysis of the target cell
(Supplementary Figure S1 online) (Ricklin et al., 2010). The
activity of the complement system is strictly regulated by cell
surface–bound and soluble inhibitors, which protect cells
against complement-mediated lysis. Complement factor H
(CFH) is an important soluble inhibitor of continuously
activated alternative pathway (de Cordoba and de Jorge,
2008; Zipfel and Skerka, 2009). It inhibits binding of
complement factor B to the C3 activation product C3b, and
displaces complement factor B cleavage product Bb from the
C3bBb complex (Supplementary Figure S1 online). CFH also
functions as a cofactor for complement factor I in the
inactivation of C3b to iC3b (Schulze et al., 1993). CFH
consists of 20 short consensus repeats (SCRs) (de Cordoba
and de Jorge, 2008). As a result of alternative splicing of the
primary transcript, CFH is present in two isoforms with similar
functions: CFH (150 kDa) and factor H-like protein-1 (FHL-1,
45 kDa) (Zipfel and Skerka, 1999). Previous studies have
shown that normal epidermal keratinocytes express
complement components and inhibitors, including CFH
(Dovezenski et al., 1992; Timar et al., 2007).
Here, we have examined the role and regulation of CFH
and FHL-1 in cSCC. The results demonstrate overexpression of
CFH and FHL-1 by cSCC cells in culture and in vivo, and that
the proportion of tumors with high expression increases with
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the progression of cSCC from early intraepithelial form, AK to
invasive cSCC. In addition, the results show that CFH
promotes proliferation and migration of cSCC cells. The results
identify CFH as tumor cell–associated biomarker for progres-
sion of SCCs of the skin.
RESULTS
Overexpression of CFH and FHL-1 in cSCC cells
The expression of complement components in cSCC cells was
determined by oligonucleotide array–based (Affymetrix, Santa
Clara, CA) expression profiling of eight cSCC cell lines (five
primary and three metastatic), and primary normal human
epidermal keratinocytes (NHEKs) established from normal skin
of five individuals. In general, the expression of mRNAs for
most complement system components, except for C1qBP and
C3, was low in NHEKs (Figure 1a). Interestingly, the mRNA
levels of certain complement components (C1r, C1s, C3, and
complement factor B) were elevated in cSCC cells, as
compared with NHEKs (Figure 1a). Among the complement
inhibitors, the expression of CFH and FHL-1, as well as
complement factor I, were markedly increased in cSCC cells
(Figure 1a).
Verification of CFH and FHL-1 mRNA expression by
quantitative real-time PCR (qPCR) revealed that the mean
levels of CFH and FHL-1 mRNA were significantly higher in
cSCC cell lines than in NHEKs (Figure 1b). Specific bands
corresponding to CFH (155 kDa) and FHL-1 (45 kDa) were
noted in conditioned media of cSCC cell lines, but not NHEKs
by western blot analysis (Figure 1c).
The expression of CFH and FHL-1 in vivo was analyzed
with qPCR of RNA samples obtained from cSCC tumors (n¼6)
and normal skin (n¼11). The expression of CFH and FHL-1
mRNAs in normal skin was low, whereas the mean expression
level of mRNAs for both inhibitors was significantly higher in
cSCCs (Figure 1d).
Overexpression of CFH and FHL-1 by tumor cells in cSCCs
in vivo
The expression of CFH and FHL-1 during progression of
cSCCs in vivo was examined by immunohistochemistry
(IHC) using tissue microarrays consisting of a large panel
of tissue samples representing different stages of epidermal
carcinogenesis, i.e., invasive cSCCs (n¼ 65), cSCCIS
(Bowen’s disease; n¼38), and premalignant lesions (AKs;
n¼ 37), as well as normal skin (n¼12). The CFH antibody
used for IHC recognizes both CFH and FHL-1. The results
showed prominent tumor cell–associated staining for CFH/
FHL-1 in cSCCs (Figure 2a–d). No clear difference in the
staining intensity was detected between inflamed and non-
inflamed cSCCs. Analysis of CFH and FHL-1 expression in
in situ cSCCs and AKs revealed in general weaker immuno-
staining intensity in most AKs (Figure 2e and f) and cSCCIS
sections (Figure 2h). The epidermal layer in normal skin
samples was in general negative for CFH/FHL-1 (Figure 2g).
Semiquantitative analysis of the immunostainings revealed
that the proportion of tumor sections showing strong staining
was significantly higher in cSCC group than in cSCCIS and
AK groups (Figure 2i).
CFH and FHL-1 expression is upregulated in Ha-ras-transformed
HaCaT cells
To gain further insight into the role of CFH in epidermal
carcinogenesis, we determined the expression of CFH and
FHL-1 mRNAs in immortalized nontumorigenic keratinocyte–
derived cell line (HaCaT) lacking functional p53, and in a
series of Ha-ras-transformed tumorigenic HaCaT cell lines (A5,
II-4, and RT3; Mueller et al., 2001). CFH and FHL-1 mRNA
levels were low in parental HaCaT cells, whereas abundant
expression of both CFH and FHL-1 mRNAs was noted in Ha-
ras-transformed HaCaT cell lines (Figure 3a). Accordingly, the
production of CFH and FHL-1 was clearly upregulated in Ha-
ras-transformed HaCaT cells, as well as in metastatic cSCC
cell line (UT-SCC-7), as determined by western blotting
(Figure 3b).
Regulation of CFH expression by cSCC cells by cytokines and
growth factors
To investigate the regulation of CFH production, UT-SCC-7
cells in culture were treated for 24 hours with inflammatory
cytokines and growth factors present in the microenvironment
of cSCCs. Analysis of the cell lysates by western blotting
indicated that the production of CFH was upregulated by
interferon-g (IFN-g), interleukin-1b (IL-1b), and transforming
growth factor-a (TGF-a), and less potently by transforming
growth factor-b (TGF-b) and tumor necrosis factor-a (TNF-a)
(Figure 4a).
CFH and FHL-1 inhibit the C3 activation cascade in the
alternative pathway by promoting the proteolytic cleavage
of C3b to iC3b (Supplementary Figure S1 online). C3
consists of a- and b-chains linked by a disulfide bond and
the N- and C-terminal regions of the a-chain are also
connected by a disulfide bond. Stepwise proteolytic inacti-
vation of C3b by complement factor I results in the
generation of smaller cleavage fragments. The C3b degra-
dation promoting activity of CFH/FHL-1 was evaluated by
analyzing C3 cleavage products in conditioned media of
cSCC cell cultures by western blot analysis. The presence of
C3a043, as a marker of CFH and FHL-1 activity, was
detected in media of primary (UT-SCC-59A and 91) and
metastatic (UT-SCC-7) cSCC cells (Figure 4b). C3b0 þ a067
fragment of iC3b generated by proteolytic cleavage and
disruption of the disulfide bridge between the C- and
N-termini of the a-chain was also detected in the media
(Figure 4b).
CFH and FHL-1 expression by cSCC cells is regulated by
extracellular signal–regulated kinase (ERK)1/2 and p38
To further investigate the regulation of CFH and FHL-1
expression in cSCC cells, primary cSCC (UT-SCC-118)
cultures were treated in parallel for 24 hours with the
inhibitor of MEK1/2 (MAPK/ERK kinase 1/2; PD98059), or
the inhibitor of p38a and p38b mitogen-activated protein
kinases (MAPKs; SB203580), or for 48h with BIRB796, an
inhibitor of all four p38 isoforms. Basal CHF and FHL-1
mRNA levels were potently downregulated by PD98059 as
compared with the untreated control cells (Figure 4c).
Interestingly, CFH and FHL-1 expression was also potently
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inhibited by p38 inhibitors SB203580 and BIRB796
(Figure 4c). These findings are interesting in the light of
previous reports showing the role of ERK1/2 and p38 MAPKs
in growth and invasion of cutaneous SCC cells (Johansson
et al., 2000; Junttila et al., 2007).
CFH and FHL-1 regulate cSCC cell proliferation and migration
To examine the functional role of CFH and FHL-1 in cSCC
cells, the expression of CFH and FHL-1 mRNAs was knocked
down using specific small interfering RNA (siRNA; Figure 5a).
A significant reduction in the number of viable cells (UT-SCC-
118) was detected at 48 and 72 hours following the inhibition
of CFH/FHL-1 expression as compared with control siRNA-
transfected cultures (Figure 5b). Inhibition of cell proliferation
was associated with potent inhibition in the levels of activated,
phosphorylated ERK1/2 at 72 hours after CHF/FHL-1 siRNA
transfection (Figure 5c). In addition, migration of UT-SCC-118
cells was significantly reduced 72 hours after knock down of
CFH/FHL-1 expression (Figure 5d). Similar results on cell
proliferation and migration were obtained with another cSCC
cell line (UT-SCC-91) (data not shown).
NHEK
Prim.
cSCC
Met.
cSCC
500 1,000
MASP2 (216968_at)
MASP1 (213749_at)
MASP1 (210680_s_at)
MASP2 (210798_x_at)
0
Signal value
C1QBP (208910_s_at)
12
CFH FHL-1
P =0.04 P =0.002
CFH FHL-1
P =0.001 P =0.006
Metastatic cSCC
NHEK
Primary cSCC
10
8
6
4
2
0 0
0.5
1
1.5
2
2.5
3
NHEK
Normal
skin
cSCC Normal
skin
cSCC
N
H
EK
 5
4
N
H
EK
 7
8
N
H
EK
 6
3
N
H
EK
 6
5
N
H
EK
 P
C
UT
-
SC
C-
10
5
UT
-
SC
C-
11
8
UT
-
SC
C-
91
UT
-
SC
C-
12
A
35
30
25
20
15
10
5
0 0
20
40
60
80
100
120
140
cSCC NHEK
CFH
FHL-1
cSCC
m
R
N
A 
ex
pr
es
sio
n 
re
la
tiv
e
 to
 β-
a
ct
in
m
R
N
A 
ex
pr
es
sio
n
re
la
tiv
e
 to
 β-
a
ct
in
m
R
N
A 
ex
pr
es
sio
n
re
la
tiv
e
 to
 β-
a
ct
in
m
R
N
A 
ex
pr
es
sio
n 
re
la
tiv
e
 to
 β-
a
ct
in
C1QBP (214214_s_at)
C1R (212067_s_at)
C1RL (218983_at)
C1RL (233645_s_at)
C1S (1555229_a_at)
C1S (208747_s_at)
C2 (1554533_at)
C2 (203052_at)
C3 (217767_at)
C4A (208451_s_at)
C4A (214428_x_at)
C4BPA (205654_at)
C4BPB (208209_s_at)
CFB (202357_s_at)
CFB (211920_at)
CFD (205382_s_at)
FHL-1 (213800_at)
CFI (203854_at)
CFI (1555564_a_at)
CFH/CFHR1 (215388_s_at)
175
46
46
30
β-Actin
Figure 1. Expression of complement system components in cutaneous squamous cell carcinoma (cSCC) cells. (a) Oligonucleotide array (Affymetrix)–based gene
expression profiling of normal human epidermal keratinocyte (NHEK) cultures (n¼ 5), primary (Prim. cSCC; n¼ 5) and metastatic (Met. cSCC; n¼ 3) cSCC cell
lines. The mean signal values for NHEKs, primary cSCC cell lines, and metastatic cSCC cell lines are shown as a heat map. (b) The expression of complement
factor H (CFH) and factor H-like protein-1 (FHL-1) mRNAs in NHEKs (n¼ 7) and cSCC cell lines (n¼8) were analyzed by quantitative real-time PCR (qPCR) and
corrected for the levels of b-actin mRNA in the same samples. The mean values for each group are indicated by horizontal bars. (c) The conditioned media of
NHEK and cSCC cell lines were analyzed by western blotting for the presence of CFH (155 kDa) and FHL-1 (45kDa). b-Actin was used as a loading control.
Migration positions of molecular weight markers (in kDa) are shown on the left. (d) CFH and FHL-1 mRNA levels in RNA samples from normal skin (n¼ 11) and
primary cSCCs (n¼ 6) were analyzed by qPCR, as in (b). The mean values for each group are indicated by horizontal bars. Statistical analysis (b, d) was performed
with the Mann–Whitney two-way U-test.
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Figure 2. Expression of CFH/FHL-1 by tumor cells in cutaneous squamous cell carcinoma (cSCC). (a–h) Sections of tissue microarray blocks containing cSCC
(n¼ 65), cSCCIS (cSCC in situ, Bowen’s disease; n¼ 38), premalignant lesions (actinic keratosis (AK); n¼ 37), and normal skin (n¼ 12) were stained with
complement factor H/factor H-like protein-1 (CFH/FHL-1) antibody. Strong cytoplasmic staining is seen in tumor cells in moderately differentiated (G2) cSCCs
(a, b) and in poorly differentiated (G3) cSCCs (c, d). Staining for CFH/FHL-1 is absent (e) or weak (f) in most AKs. Epidermal layer in normal skin is negative for
CH/FHL-1 (g). In cSCCIS tissue sections, moderate CFH/FHL-1 staining is detected in tumor cells (h). Bar¼200mm. (i) Semiquantitative analysis of CFH/FHL-1
stainings of AK, cSCCIS, and cSCC tissue sections. Intensity of tumor cell–specific immunostaining was scored negative ( ), weak (þ ), moderate (þ þ ),
and strong (þ þ þ ). The percentage of tumors with strong tumor cell–specific staining is significantly higher in cSCCs than in cSCCIS and AK sections
(P¼ 0.035; w2-test).
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Figure 3. Upregulation of complement factor H (CFH) and factor H-like protein-1 (FHL-1) expression in Ha-ras-transformed HaCaT cells. (a) Expression levels of
CFH and FHL-1 mRNAs in HaCaT cells and in tumorigenic Ha-ras-transformed HaCaT cell lines (A5, II-4, and RT3) were analyzed by quantitative real-time PCR
(qPCR) and corrected for the levels of b-actin mRNA in the same samples. (b) The cell lysates were analyzed by western blotting for the presence of CFH (155 kDa)
and FHL-1 (45 kDa). Migration positions of molecular weight markers (in kDa) are shown on the left. CFH and FHL-1 levels quantitated densitometrically and
corrected for b-actin levels in the same samples are shown below the western blots relative to levels in A5 cells (1.00).
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DISCUSSION
The complement system has an important role in host defense
as a part of innate immunity. Complement can be activated
via three distinct pathways, i.e., classical, lectin, and alter-
native pathways (Supplementary Figure S1 online). The alter-
native pathway is continuously activated in vivo. Therefore,
specific inhibitors are required to protect the host tissues from
damage exerted by complement activation (Zipfel and Skerka,
2009). CFH and its splicing variant FHL-1 are key inhibitors in
the alternative pathway. They inhibit activation of the
alternative pathway by promoting proteolytic inactivation of
C3b and by inhibiting the activity of C3 convertase C3bBb
(Supplementary Figure S1 online). Escape from immune attack
has an important role in cancer progression, and expression of
complement inhibitors, including CFH, has been documented
in malignant tumors such as bladder cancer (Cheng et al.,
2005) and ovarian cancer (Junikkala et al., 2002).
The results of this study show that tumor cells of cSCCs
produce functionally active complement inhibitors CFH and
FHL-1 in culture and also express these inhibitors in vivo. The
expression of the mRNAs for CFH and FHL-1 was elevated in
most cSCC cell lines studied and in all cSCC tumors compared
with NHEKs or normal skin. Production of CFH and FHL-1
was also detected by cSCC cell lines, but not by NHEKs. For
further investigation of CFH and FHL-1 expression in vivo we
performed IHC analysis of tissue microarrays consisting of a
large panel of cSCCs, cSCCIS, and AKs. The antibody used
does not distinguish between CFH and FHL-1, but the results
of qPCR of tumor tissue RNA verified that both CFH and
FHL-1 mRNAs were expressed in cSCCs in vivo. Results of
IHC analysis revealed that CFH and FHL-1 were specifically
expressed by tumor cells, whereas epidermal layer in normal
skin was negative. Although the most prominent staining for
CFH/FHL-1 was detected in cSCCs, moderate and even strong
staining was also noted in a subset of AK and cSCCIS sections
indicating that the expression is induced early in cSCC
progression. Analysis of Ha-ras-transformed HaCaT cells
representing different stages of epidermal carcinogenesis
(Mueller et al., 2001) revealed that CFH and FHL-1
expression was low in parental HaCaT cells and markedly
higher in ras-transformed HaCaT cells. Thus, inactivation of
p53, an early event in epidermal carcinogenesis, is not
sufficient for induction of CFH and FHL-1 expression, but
activation of ras signaling is also required. Constitutive
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Figure 4. Regulation of complement factor H (CFH) expression in cutaneous squamous cell carcinoma (cSCC) cells. (a) Metastatic cSCC cell line (UT-SCC-7)
cultures were treated with interleukin-1b (IL-1b (10ng/ml), interferon-g (IFN-g (100 U/ml), transforming growth factor-b (TGF-b; 5 ng/ml), tumor necrosis factor-a
(TNF-a; 20 ng/ml), and transforming growth factor-a (TGF-a; 50 ng/ml) for 24 h. Cell lysates were analyzed by western blotting for CFH (155 kDa). CFH levels
quantitated densitometrically and corrected for b-actin levels in the same samples are shown below the western blots relative to levels in untreated control (Ctr)
cells (1.00). (b) Primary (UT-SCC-59A and UT-SCC-91) and metastatic (UT-SCC-7) cSCC cells were cultured for 24 hours. UT-SCC-7 cell line was treated in parallel
with TGF-b (5 ng/ml). The conditioned media were analyzed for C3 inactivation fragments C3a043 and C3b0 þ a067 as indicators for CFH/FHL-1 activity with
western blotting using C3 antibody. b-Actin levels were determined in the corresponding cell lysates as the loading control. Migration positions of molecular
weight markers (in kDa) are shown on the left. (c) cSCC cells (UT-SCC-118) in culture were treated for 24 hours with MEK1/2 inhibitor PD98059 (PD; 30mM) and
with p38 inhibitor SB203580 (SB; 10mM), for 48h with p38 inhibitor and BIRB796 (10mM) as indicated. Levels of CFH and FHL-1 mRNAs were analyzed by qPCR
and corrected for the levels of b-actin mRNA in the same samples.
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activation of ras signaling results in permanent activation of
ERK1/2 signaling in cSCC cells (Toriseva et al., 2012).
Accordingly, our results showed that CFH and FHL-1
expression in cSCC cells was potently downregulated by
inhibition of ERK1/2 signaling. Interestingly, p38 MAPK
signaling was also found to have an important role in
regulating basal CFH and FHL-1 expression. Together these
results identify CFH and FHL-1 as targets for ERK1/2 and p38
MAPK signaling cascades in cSCC cells.
It has been proposed that tumor cells utilize complement
inhibitors for immune evasion (Gorter and Meri, 1999). CFH
and FHL-1 have also been suggested to have a role in the
escape of malignant cells from complement-mediated
cytotoxicity in colon (Wilczek et al., 2008), lung (Ajona
et al., 2004; Ajona et al., 2007), ovarian (Junnikkala et al.,
2002), and bladder cancers (Cheng et al., 2005) and in
glioblastoma (Junnikkala et al., 2000). CFH has also been
shown to bind osteopontin and bone sialoprotein, which in
this way may promote CFH-mediated inhibition of cell lysis by
sequestering CFH to cell surface and blocking the activity of
the alternative pathway (Fedarko et al., 2000). Our results
show that certain complement components are also
overexpressed in cSCC cells as compared with NHEKs
(Figure 1a). C3 is a key component of complement cascade
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samples (lower panels). (b) Number of viable cells was determined after siRNA transfection using WST-1 assay (n¼ 3; ***Po0.0001, t-test). (c) Cell lysates were
analyzed for the levels of phosphorylated extracellular signal–regulated kinase (ERK)1/2 (p-ERK1/2), total ERK1/2, phosphorylated p38 (p-p38), and total p38 by
western blotting 72 hours after siRNA transfection (left panel). p-ERK1/2 blots were quantitated by densitometry and corrected for the levels of total ERK1/2 (right
panel). (d) Control and CFH/FHL-1 siRNA–transfected cells were incubated for 48 hours. To inhibit cell division, cells were then treated with hydroxyurea (1 mM)
for 6 hours. A scratch was created with a pipet tip in the cell monolayer and incubation was continued in 1% fetal calf serum in DMEM and 0.5 mM hydroxyurea
for 24 h. A representative image of the experiment is shown (upper panel). Quantitation of the relative migration rate of cultures is shown (lower panel; n¼ 3,
P¼ 0.03, t-test).
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as activation of all three different pathways leads to activation
of C3. Our results show that although NHEKs express C3, the
expression is elevated in cSCC cells. These findings provide a
possibility for complement activation by cSCC cells, which in
this way may promote inflammation and attract phagocytic
cells to the site of activation. Our results also provide evidence
that cSCC cells produce functionally active CFH, as shown by
the presence of iC3 in culture media, which reflects CFH
activity and is a marker for recent complement activation and
inhibition (Schulze et al., 1993). Thus, cSCCs appear to create
a microenvironment that protects the cells from complement-
mediated cell killing.
CFH has additional documented functions that may have a
role in cancer progression. CFH has been shown to regulate
activation of matrix metalloproteinase-2 and 3 by an interac-
tion with three small integrin-binding ligand N-linked glyco-
proteins (SIBLINGs) osteopontin, bone sialoprotein, and dentin
matrix protein-1 (Fedarko et al., 2004). Furthermore, FHL-1
has been shown to promote cell adhesion (Hellwage et al.,
1997; Zipfel and Skerka, 1999). Our results provide evidence
for two other previously unreported cellular functions of CFH
and FHL-1 relevant in cancer progression, i.e., regulation of
cell proliferation and migration. In this respect, it is interesting,
that knockdown of CFH and FHL-1 expression resulted in
potent inhibition of ERK1/2 activation in cSCC cells. CFH and
FHL-1 have been shown to bind complement receptor 3
(CD11b/CD18; aMb2 integrin) on neutrophils (Losse et al.,
2010), but it is not known whether this receptor has any role
in mediating effects of CFH on cSCC cells. Inflammation is
noted in a subset of cSCCs. Interestingly, inflammatory
cytokines IFN-g, IL-1b, and TNF-a upregulated the
expression of CFH by cSCC cells. These results are in
accordance with previous studies showing upregulation of
CFH expression by IFN-g in epidermal keratinocytes (Timar
et al., 2006).
Taken together, the results of the present study show that
cSCCs express CFH and FHL-1, the main inhibitors of the
alternative pathway of the complement system. Apparently,
these complement regulators have an important role in the
progression of cSCCs by allowing tumor cells to escape
complement attack. In conclusion, our results show that
CFH and FHL-1 expression is specifically induced during
cutaneous carcinogenesis, suggesting these complement inhi-
bitors as putative diagnostic biomarkers and as potential
targets for anticancer therapy in skin SCCs.
MATERIALS AND METHODS
Ethical issues
The study was conducted according to the Declaration of Helsinki.
The use of archival tissue specimens, and collection of normal skin
and cSCC tissues was approved by the Ethics Committee of the
Hospital District of Southwest Finland. The study was carried out with
the permission of Turku University Hospital and with written
informed consent of all patients before surgery.
Cell cultures
NHEKs were established from skin samples obtained from mammo-
plasty (n¼ 6). Primary human epidermal keratinocytes (NHEK-PC)
were obtained from PromoCell (Heidelberg, Germany). NHEKs were
cultured in keratinocyte growth medium-2 with supplement mix
and calcium chloride (PromoCell), L-glutamine and penicillin–
streptomycin mixture (Gibco, Paisley, Scotland, UK) (Junttila et al.,
2007). The spontaneously immortalized nontumorigenic human
keratinocyte–derived cell line (HaCaT; Boukamp et al., 1988) and
three Ha-ras-transformed tumorigenic HaCaT cell lines (A5, II-4, and
RT3; Boukamp et al., 1990) were kindly provided by Dr Norbert
Fusenig (Deutsche Krebsforschungszentrum, Heidelberg, Germany).
A5 cells form benign, II-4 cells low-grade malignant, and RT3 cells
high-grade malignant tumors in vivo in nude mice (Mueller et al.,
2001). cSCC cell lines (n¼ 8) were established from the cSCCs at the
time of operation in Turku University Hospital (Farshchian et al.,
2011). Of these, five were derived from primary SCCs (UT-SCC-12A,
91, -105, -111, and -118) and three from metastases (UT-SCC-7,
-59A, and -115). SCC and HaCaT cells were cultured in DMEM (Flow
Laboratories, Irvine, UK) supplemented with 10% fetal calf serum
(FCS), 100 IU penicillin G, 100mg/ml streptomycin, and 2 mM
L-glutamine. G418 (200mg/ml) was included in A5, II-4, and RT3
cell medium.
Microarray-based expression profiling
The gene expression profiling on NHEKs (n¼ 5) and cSCC cell lines
(n¼ 8) was assessed using Affymetrix Human Genome U133 Plus 2.0
array (Affymetrix, Santa Clara, CA) and the data analyses were
performed at the Microarray Centre of Turku Centre for Biotechnol-
ogy. Normalization of the arrays was performed using RMA assay,
Chipster software (CSC – IT Center for Science, Espoo, Finland). Mean
signal level of NHEKs was used as the control for signal level of each
cell line. Sequence specificity of Affymetrix probes was verified by
BLAST search.
Tissue RNA
Primary cSCC (n¼ 6) samples were obtained from surgically removed
tumors in Turku University Hospital (Farshchian et al., 2011). Normal
skin samples (n¼ 11) were obtained during mammoplasty operation
in Turku University Hospital and from the upper arm of healthy
volunteers. Total RNA was isolated from the tissue samples and
analyzed by qPCR (Stokes et al., 2010).
qPCR
cDNA was synthesized from total RNA using 1mg of RQ1 DNase–
treated (Promega M610A; Promega, Madison, WI) RNA, Random
Primers (Promega C118A), M-MLV Reverse Transcriptase (Promega
M531A) and RNase H minus polymerase (Promega M368B). qPCR
analysis of cDNA samples for CFH and FHL-1 mRNA levels was
performed in duplicate with specific primers and fluorescent probes
(Supplementary Table S1 online; Stokes et al., 2010). In each
measurement, range of the threshold cycle values were o5% of the
mean. The results were corrected for the levels of b-actin or
glyceraldehyde-3-phosphate dehydrogenase mRNA in the same
samples.
Tissue samples and IHC
Altogether 152 formalin-fixed paraffin-embedded tissue samples from
sporadic, UV-induced cSCC (n¼ 65; mean age 77 years, range 45–96
years), cSCCIS (Bowen’s disease; n¼ 38; mean age 82 years, range
70–95 years), AK (n¼ 37; mean age 78 years, range 58–95 years), and
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normal skin (n¼ 12) were obtained from the archives of the Depart-
ment of Pathology, Turku University Hospital. Tissue microarray
blocks were generated as described (Kononen et al., 1998). The
sections were stained with mouse monoclonal anti-CFH antibody,
which also detects FHL-1 (clone OX-24, AbD Serotec, Oxford, UK),
diluted (1:850) in PBS containing 1.5% horse serum. Immuno-
stainings were performed with avidin–biotin–peroxidase complex
technique (VectaStain ABC Kit; Vector Laboratories, Burlingame,
CA) in combination with diaminobentzidine and Mayer’s hematox-
ylin (Sigma-Aldrich Chemie, Steinheim, Germany) as a counterstain
(Kivisaari et al., 2008). For negative control stainings, the primary
antibody was replaced with PBS. The staining intensity was scored by
two independent observers (PR and MK) as negative ( ), weak (þ ),
moderate (þ þ ), or strong (þ þ þ ) based on the intensity of
cytoplasmic staining.
Western blot analysis
The production of CFH by NHEKs and cSCC cell lines was
determined by western blotting of cell lysates and media using
specific polyclonal goat anti-CFH antibody (1:1000; Calbiochem,
La Jolla, CA). The levels of C3 cleavage products in conditioned
media were determined using polyclonal goat anti-C3 antibody
(1:1000; Calbiochem). UT-SCC-7 cells were maintained in serum-
free DMEM for 24 hours, and then treated with IL-1b (10 ng/ml;
Calbiochem), IFN-g (100 U/ml; Promega), TGF-b1 (5 ng/ml; Sigma
Aldrich, St Louis, MO), TNF-a (20 ng/ml; Sigma Aldrich), or TGF-a
(50 ng/ml; Peprotech, Stockholm, Sweden) for 24 hours. To study the
role of MAPK signaling on expression of CFH, cSCC cell cultures
were serum starved for 24 hours and then treated with MEK1/2
inhibitor PD98059 (30mM), or with p38a/p38b inhibitor SB203580
(10mM), for 24h or with p38a/p38b/p38g/p38d inhibitor BIRB796
(10mM) (all from Calbiochem) for 48 hours.
siRNA knockdown of CFH/FHL-1 expression
cSCC cells were grown to 50% confluency and transfected with
negative control siRNA or siRNA targeting both CFH and FHL-1
(75 nM; Qiagen, Hilden, Germany) using siLentFect Lipid Reagent
(Bio-Rad, Hercules, CA) (Kivisaari et al., 2010). Cells were harvested
24, 48, and 72 hours after transfection, the levels of CFH and FHL-1
mRNAs were determined by qPCR, and CFH and FHL-1 protein
levels by western blotting.
Cell proliferation
cSCC cells were transfected with negative control siRNA or
CFH/FHL-1 siRNA (75 nM). After 24 hours transfected cells (104
cells/well) were seeded on 96-well plates. The number of viable
cells at 0, 24, 48, and 72 hours was determined by WST-1 cell
proliferation reagent (Roche Diagnostics, Mannheim, Germany). The
experiment was performed with 5–6 parallel wells in each time point
with two cSCC cell lines (UT-SCC-91 and 118). The activation of
ERK1/2 and p38 was verified by western blotting of the cell lysates
with antibodies specific for phospho-ERK1/2 and phospho-p38
(Cell Signaling Technology, Berverly, MA), respectively.
Cell migration
Cells were transfected with negative control siRNA or CFH/FHL-1
siRNA (75 nM) and grown to confluency in complete growth medium
for 48 hours. To inhibit cell division, cells were treated with 1 mM
hydroxyurea (Sigma Aldrich) in DMEM with 1% FCS for 6 hours. A
scratch in the cell monolayer was created with pipet tip and incubation
was continued in DMEM with 1% FCS and 0.5 mM hydroxyurea for
24 hours. Microscopy was performed with Olympus IX70 (Olympus
Optical, Tokyo, Japan) inverted microscope. Cell migration was
studied in three independent experiments with two cSCC cell lines
(UT-SCC-91 and 118). In each experiment there were three parallel
wells and the cell-free area was measured from four areas in one well
with ImageJ software (Schneider et al., 2012).
Statistical analysis
Mann–Whitney U-test was used for determining the significance of
differences between two non-normally distributed independent sam-
ple groups for qPCR. Two independent samples t-tests was used for
proliferation and migration assays. w2-Test was used to compare IHC
staining intensity.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Sari Pitka¨nen, Johanna Markola-Wa¨rn, and Sinikka Kollanus for
expert technical assistance. The study was supported by the Academy of
Finland (project 137687), the Finnish Cancer Research Foundation, Sigrid
Juse´lius Foundation, and Turku University Hospital EVO grant (project 13336),
and by personal grants to PR from Turku University Foundation, Finnish
Dermatological Association, and Dermatopathology Society. PR is a student in
the National Graduate School of Clinical Investigation (CLIGS).
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Ajona D, Castano Z, Garayoa M et al. (2004) Expression of complement factor
H by lung cancer cells: effects on the activation of the alternative pathway
of complement. Cancer Res 64:6310–8
Ajona D, Hsu YF, Corrales L et al. (2007) Down-regulation of human
complement factor H sensitizes non-small cell lung cancer cells to
complement attack and reduces in vivo tumor growth. J Immunol
178:5991–8
Boukamp P, Petrussevska RT, Breitkreutz D et al. (1988) Normal keratinization
in a spontaneously immortalized aneuploid human keratinocyte cell line.
J Cell Biol 106:761–71
Boukamp P, Stanbridge EJ, Foo DY et al. (1990) c-Ha-ras oncogene
expression in immortalized human keratinocytes (HaCaT) alters growth
potential in vivo but lacks correlation with malignancy. Cancer Res
50:2840–7
Cheng ZZ, Corey MJ, Parepalo M et al. (2005) Complement factor H as a
marker for detection of bladder cancer. Clin Chem 51:856–63
de Co´rdoba SR, de Jorge EG (2008) Translational mini-review series on
complement factor H: genetics and disease associations of human
complement factor. Clin Exp Immunol 151:1–13
Coussens L, Werb Z (2002) Inflammation and cancer. Nature 420:860–7
Dovezenski N, Billetta R, Gigli I (1992) Expression and localization of
proteins of the complement system in human skin. J Clin Invest
90:2000–12
Farshchian M, Kivisaari A, Ala-aho R et al. (2011) Serpin peptidase inhibitor
clade A member 1 (SerpinA1) is a novel biomarker for progression of
cutaneous squamous cell carcinoma. Am J Pathol 179:1110–9
Fedarko NS, Fohr B, Robey PG et al. (2000) Factor H binding to bone
sialoprotein and osteopontin enables tumor cell evasion of complement-
mediated attack. J Biol Chem 275:16666–72
PM Riihila¨ et al.
Complement Factor H in Skin Squamous Cell Carcinoma
www.jidonline.org 505
Fedarko NS, Jain A, Karadag A et al. (2004) Three small integrin binding ligand
N-linked glycoproteins (SIBLINGs) bind and activate specific matrix
metalloproteinases. FASEB J 18:734–6
Gorter A, Meri S (1999) Immune evasion of tumor cells using membrane-
bound complement regulatory proteins. Immunol Today 20:576–82
Hellwage J, Kuhn S, Zipfel PF (1997) The human complement regulatory
factor-H-like protein 1, which represents a truncated form of factor H,
displays cell-attachment activity. Biochem J 326:321–7
Johansson N, Ala-aho R, Uitto V et al. (2000) Expression of collagenase-3
(MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is
dependent on the activity of p38 mitogen-activated protein kinase. J Cell
Sci 113:227–35
Junnikkala S, Jokiranta TS, Friese MA et al. (2000) Exceptional resistance of
human H2 glioblastoma cells to complement-mediated killing by
expression and utilization of factor H and factor H-like protein 1.
J Immunol 164:6075–81
Junnikkala S, Hakulinen J, Jarva H et al. (2002) Secretion of soluble
complement inhibitors factor H and factor H-like protein (FHL-1) by
ovarian tumour cells. Br J Cancer 87:1119–27
Junttila MR, Ala-Aho R, Jokilehto T et al. (2007) p38a and p38d mitogen-
activated protein kinase isoforms regulate invasion and growth of head
and neck squamous carcinoma cells. Oncogene 26:5267–79
Kivisaari AK, Kallajoki M, Ala-aho R et al. (2010) Matrix metalloproteinase-7
activates heparin-binding epidermal growth factor-like growth factor in
cutaneous squamous cell carcinoma. Br J Dermatol 163:726–35
Kivisaari AK, Kallajoki M, Mirtti T et al. (2008) Transformation-specific matrix
metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour
cells in epidermolysis bullosa-associated squamous cell carcinomas.
Br J Dermatol 158:778–85
Kononen J, Bubendorf L, Kallioniemi A et al. (1998) Tissue microarrays for
high-throughput molecular profiling of tumor specimens. Nat Med 4:
844–7
Losse J, Zipfel PF, Jo´zsi M (2010) Factor H and factor H-related protein 1 bind
to human neutrophils via complement receptor 3, mediate attachment
to Candida albicans, and enhance neutrophil antimicrobial activity.
J Immunol 184:912–21
Madan V, Lear JT, Szeimies RM (2010) Non-melanoma skin cancer. Lancet
375:673–85
Mueller MM, Peter W, Mappes M et al. (2001) Tumor progression of skin
carcinoma cells in vivo promoted by clonal selection, mutagenesis, and
autocrine growth regulation by granulocyte colony-stimulating factor
and granulocyte-macrophage colony-stimulating factor. Am J Pathol
159:1567–79
Ratushny V, Gober MD, Hick R et al. (2012) From keratinocyte to cancer: the
pathogenesis and modeling of cutaneous squamous cell carcinoma. J Clin
Invest 122:464–72
Ricklin D, Hajishengallis G, Yang K et al. (2010) Complement: a key system for
immune surveillance and homeostasis. Nat Immunol 11:785–97
Rogers HW, Weinstock MA, Harris AR et al. (2010) Incidence estimate of
nonmelanoma skin cancer in the United States. Arch Dermatol 146:283–7
Rutkowski MJ, Sughrue ME, Kane AJ et al. (2010) The complement cascade as
a mediator of tissue growth and regeneration. Inflamm Res 59:897–905
Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years
of image analysis. Nature Methods 9:671–5
Schulze M, Pruchno CJ, Burns M et al. (1993) Glomerular C3c localization
indicates ongoing immune deposit formation and complement activation
in experimental glomerulonephritis. Am J Pathol 142:179–87
Stokes A, Joutsa J, Ala-aho R et al. (2010) Expression profiles and clinical
correlations of degradome components in the tumor microenvironment of
head and neck squamous cell carcinoma. Clin Cancer Res 16:2022–35
Timar KK, Dallos A, Kiss M et al. (2007) Expression of terminal complement
components by human keratinocytes. Mol Immunol 44:2578–86
Timar KK, Pasch MC, van den Bosch NH et al. (2006) Human keratinocytes
produce the complement inhibitor factor H: synthesis is regulated by
interferon-g. Mol Immunol 43:317–25
Toriseva M, Ala-aho R, Peltonen S et al. (2012) Keratinocyte growth factor
induces gene expression signature associated with suppression of malig-
nant phenotype of cutaneous squamous carcinoma cells. PLoS One
7:e33041
Wilczek E, Rzepko R, Nowis D et al. (2008) The possible role of factor H in
colon cancer resistance to complement attack. Int J Cancer 122:2030–7
Zipfel PF, Skerka C (1999) FHL-1/reconectin: a human complement and
immune regulator with cell-adhesive function. Immunol Today 20:135–40
Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat
Rev Immunol 9:729–40
PM Riihila¨ et al.
Complement Factor H in Skin Squamous Cell Carcinoma
506 Journal of Investigative Dermatology (2014), Volume 134
